CN111920763A - 一种香附精油抗敏霜及其制备工艺 - Google Patents
一种香附精油抗敏霜及其制备工艺 Download PDFInfo
- Publication number
- CN111920763A CN111920763A CN202010989101.1A CN202010989101A CN111920763A CN 111920763 A CN111920763 A CN 111920763A CN 202010989101 A CN202010989101 A CN 202010989101A CN 111920763 A CN111920763 A CN 111920763A
- Authority
- CN
- China
- Prior art keywords
- percent
- cream
- essential oil
- water
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 112
- 239000000341 volatile oil Substances 0.000 title claims abstract description 83
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 69
- 244000075634 Cyperus rotundus Species 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 244000150195 Cyperus longus Species 0.000 title claims abstract description 17
- 235000018109 Cyperus longus Nutrition 0.000 title 1
- 235000005010 Scirpus paludosus Nutrition 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 53
- 235000016854 Cyperus rotundus Nutrition 0.000 claims abstract description 33
- 239000011159 matrix material Substances 0.000 claims abstract description 27
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 21
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 21
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 21
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 21
- 229960001631 carbomer Drugs 0.000 claims abstract description 21
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 21
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008117 stearic acid Substances 0.000 claims abstract description 21
- 239000004166 Lanolin Substances 0.000 claims abstract description 19
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 19
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940039717 lanolin Drugs 0.000 claims abstract description 19
- 235000019388 lanolin Nutrition 0.000 claims abstract description 19
- 229920000570 polyether Polymers 0.000 claims abstract description 19
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 229940099259 vaseline Drugs 0.000 claims abstract description 13
- 239000003921 oil Substances 0.000 claims description 28
- 241000234653 Cyperus Species 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 239000003871 white petrolatum Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 229960004274 stearic acid Drugs 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 235000019271 petrolatum Nutrition 0.000 claims description 4
- 239000004264 Petrolatum Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229940066842 petrolatum Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 4
- 239000012071 phase Substances 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- GIGKXOAUYMWORB-OSQNNJELSA-N isopatchoulenone Chemical compound C[C@@H]1CC[C@@H]2CC3=C(C)C(=O)C[C@]13C2(C)C GIGKXOAUYMWORB-OSQNNJELSA-N 0.000 description 14
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 229930004725 sesquiterpene Natural products 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000013517 stratification Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 238000006748 scratching Methods 0.000 description 5
- 230000002393 scratching effect Effects 0.000 description 5
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- -1 sesquiterpene aldehyde Chemical class 0.000 description 4
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003260 anti-sepsis Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 241000234646 Cyperaceae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002861 doxepin hydrochloride Drugs 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种香附精油抗敏霜及其制备工艺。具体提供了一种霜剂基质和该霜剂基质制得的香附精油抗敏霜,该霜剂基质是由下述重量百分比的原料制得的:甘油聚醚2.00%~10.00%、三乙醇胺2.00%~4.00%、卡波姆0.10%~0.50%、十二烷基硫酸钠0.50%~2.00%、羊毛脂1.00%~5.00%、凡士林10.00%~30.00%、硬脂酸4.0%0~20.00%,其余为水。本发明提供的霜剂基质光泽度、细腻性、涂展性、成形性好,外观、离心稳定性、耐寒性、耐热性和pH值的综合性能优异。以该霜剂基质与香附精油为原料制得的香附精油抗敏霜不仅具有前述优异的综合性能,还具有良好的抗敏效果,有效成分含量高,质量稳定,具有优异的长期储存稳定性,应用前景广阔。
Description
技术领域
本发明属于药剂制备领域,具体涉及一种香附精油抗敏霜及其制备工艺。
背景技术
常见的皮肤过敏反应在医学上称作超敏反应,又称变态反应,是指机体受到某些抗原刺激时,出现以生理功能紊乱或组织细胞损伤为主的异常的特异性免疫应答。随着全球生态环境的不断恶化,加上人们对皮肤健康意识的提高,皮肤敏感与刺激的感知率和关注度逐渐上升。据不完全统计,全球自我感觉敏感性肌肤的人群越来越多,其中男性占38%,女性占61%。因此,抗过敏化妆品受到了越来越广泛的关注。抗过敏化妆品的种类繁多,包括抗敏霜、抗敏乳液、抗敏面膜、抗敏洁面乳、抗敏沐浴露等等,其中,抗敏霜是一种霜剂,其由于使用方便、易携带、易储存等优点而被大多数人所接受。
抗敏霜中包括抗敏活性成分和霜剂基质,其中,霜剂基质中通常包括乳化剂、增稠剂、保湿剂等成分,一般分为水相和油相。霜剂基质的成分和配比是影响抗敏霜的外观(比如光泽、细腻性、涂展性、成形性)和稳定性的关键因素。研究出一种稳定性、光泽度、细腻性、涂展性、成形性等综合性能优异的抗敏霜一直是本领域研究者的目标。
抗敏霜中的抗敏活性成分是发挥抗过敏作用的成分。为了提高抗过敏化妆品对皮肤的安全性,从植物中提取得到的安全无毒的抗敏活性成分引起了人们的关注。
香附是莎草科植物莎草Cyperus rotundus L.的干燥根茎,被称为“疏肝理气之良药”,在不断的研究中发现香附还具有治疗其他疾病的作用。早在《雷公炮制药性解》中曾提到香附有消风祛痒的功效,在现代研究中,相继有文献报道发现香附有抗过敏抗炎的作用。Jeong Ho Jin等(Anti-allergic activity of sesquiterpenes from the rhizomes ofCyperus rotundus.Archives of Pharmacal Research,2011,34(2).)研究了香附抗过敏作用的机制,并发现倍发半萜类是其发挥抗过敏作用的主要成分。香附挥发油是香附根茎的主要活性部位,是生物活性挥发性次生代谢产物的主要来源,而香附挥发油的主要成分就是倍半萜类物质,如氧化倍半萜烯衍生物、倍半萜烯醛、倍半萜烯环氧化物、倍半萜烯烃和倍半萜烯酮。
目前还没有将香附精油用来制备抗敏霜的报道,更没有报道给出如何制得稳定性、光泽度、细腻性、涂展性、成形性等综合性能优异的香附精油抗敏霜的启示。
发明内容
本发明的目的在于提供一种香附精油抗敏霜及其制备工艺。
本发明提供了一种霜剂基质,它是由下述重量百分比的原料制得的:甘油聚醚2.00%~10.00%、三乙醇胺2.00%~4.00%、卡波姆0.10%~0.50%、十二烷基硫酸钠0.50%~2.00%、羊毛脂1.00%~5.00%、凡士林10.00%~30.00%、硬脂酸4.0%0~20.00%,其余为水。
进一步地,它是由下述重量百分比的原料制得的:甘油聚醚6.00%、三乙醇胺3.00%、卡波姆0.20%~0.40%、十二烷基硫酸钠1.25%~1.75%、羊毛脂2.00%、凡士林10.00%~12.00%、硬脂酸10.00%~14.00%,其余为水;
优选的,它是由下述重量百分比的原料制得的:甘油聚醚6.00%、三乙醇胺3.00%、卡波姆0.20%~0.39%、十二烷基硫酸钠1.25%~1.50%、羊毛脂2.00%、凡士林11.00%~11.49%、硬脂酸10.00%~14.00%,其余为水。
进一步地,它是由下述重量百分比的原料制得的:甘油聚醚6.00%、三乙醇胺3.00%、卡波姆0.30%~0.39%、十二烷基硫酸钠1.25%~1.27%、羊毛脂2.00%、凡士林11.00%~11.49%、硬脂酸13.89%~14.00%,其余为水。
进一步地,所述甘油聚醚为甘油聚醚-26;
和/或,所述凡士林为白凡士林。
进一步地,所述霜剂基质中还包括防腐剂,所述防腐剂的重量百分比为0.05%~0.20%,优选为0.10%,所述防腐剂优选为尼铂金甲酯。
本发明还提供了上述霜剂基质的制备方法,所述方法包括以下步骤:
(1)将甘油聚醚、三乙醇胺、卡波姆、十二烷基硫酸钠、水混合,加热融化,得水相;
(2)将羊毛脂、凡士林、硬脂酸混合,加热融化,得油相;
(3)将水相和油相混合均匀,凝固后即得;
优选的,步骤(1)中,所述加热温度为75~85℃;和/或,步骤(2)中,所述加热温度为75~85℃;和/或,步骤(3)中,所述混合时的温度为75~85℃。
本发明还提供了一种香附精油抗敏霜,它是由香附精油和霜剂基质组成的,霜剂基质如上所述,香附精油和霜剂基质的重量之比为(1~5):100。
进一步地,所述香附精油和霜剂基质的重量之比为3:100。
进一步地,所述香附精油的制备方法为:取香附,加水加热提取,收集挥发油,即得;所述香附与水的质量体积比优选为1:(2~8)g/ml,更优选为1:5g/ml;所述加热温度为100℃;所述提取时间为3~7小时,优选为5小时。
本发明还提供了上述香附精油抗敏霜的制备方法,所述方法包括以下步骤:
(1)将甘油聚醚、三乙醇胺、卡波姆、十二烷基硫酸钠、水混合,加热融化,得水相;
(2)将羊毛脂、凡士林、硬脂酸混合,加热融化,得油相;
(3)将香附精油、水相和油相混合均匀,凝固后即得;
优选的,步骤(1)中,所述加热温度为75~85℃;和/或,步骤(2)中,所述加热温度为75~85℃;和/或,步骤(3)中,所述混合时的温度为75~85℃。
本发明中,香附挥发油即香附精油。
实验结果表明,本发明提供的霜剂基质光泽度、细腻性、涂展性、成形性好,外观、离心稳定性、耐寒性、耐热性和pH值的综合性能优异。以该霜剂基质与香附精油为原料制得的香附精油抗敏霜不仅具有前述优异的综合性能,还具有良好的抗敏效果,有效成分含量高,质量稳定,具有优异的长期储存稳定性,应用前景广阔。
本发明霜剂基质与香附精油的制备方法简单、条件温和、耗时短,适合商业化生产。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
本发明所用原料与设备均为已知产品,通过购买市售产品所得。
实施例1:空白霜剂的制备
空白霜剂由水相和油相组成,其中,水相组成为:甘油聚醚-26 6g、三乙醇胺3g、卡波姆0.39g、十二烷基硫酸钠1.27g、水61.96g;油相组成为:羊毛脂2g、白凡士林11.49g、硬脂酸13.89g。
制备方法如下:将油相与水相分别在75-85℃水浴加热熔化,保温;然后在不断搅拌下将熔化后的油相加入水相,搅拌均匀、放冷凝固后即得空白霜剂。
实施例2:香附精油抗敏霜的制备
香附精油抗敏霜由霜剂基质和香附挥发油组成,香附挥发油的重量为霜剂基质重量的3%。
霜剂基质由水相和油相组成,其中,水相组成为:甘油聚醚-26 6g、三乙醇胺3g、卡波姆0.39g、十二烷基硫酸钠1.27g、水61.96g;油相组成为:羊毛脂2g、白凡士林11.49g、硬脂酸13.89g。
制备方法如下:
(1)制备香附挥发油:取100g香附,加500ml水(料液比1:5g/ml),在100℃下提取5小时,收集挥发油,即得香附挥发油。
(2)油相与水相分别在75-85℃水浴加热熔化,保温;将香附挥发油加入油相搅拌均匀,再在不断搅拌下将熔化后的水相加入油相,搅拌均匀、放冷凝固后即得香附精油抗敏霜。
实施例3:空白霜剂的制备
空白霜剂由水相和油相组成,其中,水相组成为:甘油聚醚-26 6g、三乙醇胺3g、卡波姆0.3g、十二烷基硫酸钠1.25g、水62.45g;油相组成为:羊毛脂2g、白凡士林11g、硬脂酸14g。
制备方法同实施例1。
实施例4:香附精油抗敏霜的制备
香附精油抗敏霜由霜剂基质和香附挥发油组成,香附挥发油的重量为霜剂基质重量的3%。
霜剂基质由水相和油相组成,其中,水相组成为:甘油聚醚-26 6g、三乙醇胺3g、卡波姆0.3g、十二烷基硫酸钠1.25g、水62.45g;油相组成为:羊毛脂2g、白凡士林11g、硬脂酸14g。
制备方法同实施例2。
以下通过实验例证明本发明的有益效果。
实验例1:基质处方筛选实验
1、实验对象
按照表1所示的比例,以甘油聚醚-26(6g)、三乙醇胺(3g)、卡波姆(见表1)、十二烷基硫酸钠(见表1)、水(总重量100g,其余为水)为水相,以羊毛脂(2g)、白凡士林(见表1)、硬脂酸(见表1)为油相,参照实施例1的方法制得不同配方的未载药的霜剂基质(即空白霜剂)。
2、评价方法
(1)外观:以霜剂的光泽,细腻性,涂展性,成形性为考察指标,在室温和非阳光直射下目测观察,测试霜剂的外观得分。外观得分=光泽*5%+细腻性*15%+细腻性*60%+涂展性*20%。
光泽:白色为最佳100分,乳黄色80分,黄色为60分,棕色0分。
细腻性:无颗粒状物、细小斑点、气泡100分;有少量颗粒状物、细小斑点、气泡80分;有大量颗粒状物和细小斑点、气泡60分;有块状物及白斑、气泡40分;全部结块0分。
涂展性:基质极易涂抹且表面无白条100分;基质易涂抹,表面有少许白条残留80分;基质易涂布但表面有大量白条60分;基质不易涂布且表面有大量白条残留40分;基质黏度太大无法涂布0分。
成形性:清爽湿润无油腻感且黏度刚好100分;轻微油腻且黏度刚好80分;轻微油腻但稍稀或稍微黏度大60分;轻微油腻且太稀40分;油腻且黏度大20分;非常油腻无法涂抹且黏度非常大0分。
(2)离心稳定性:于离心管中注入试样约2/3高度(3.5ml)并装实,用塞子塞好。然后放入预先调节到38℃的电热恒温培养箱内,保持l h后,立即移入离心机中,并将离心机调整到2000r/min的离心速度,离心30min取出观察霜剂有无分层现象。以总分100分为最高分进行评价,即离心稳定性得分=100-30(分层严重);得分=100-20(中等分层);得分=100-10(轻微分层)。(分层距离,≤0.2ml的分层属于轻微分层,0.2~0.5ml分层为中等分层,≥0.5ml分层属于严重分层)。
(3)耐寒性:将试样倾入两只相同试管内,高度不超过80mm,塞上干净的塞子。把一支待验的试管置于预先调节至~8℃的冰箱内,经24h后取出,恢复至室温后与另一支试管的试样进行目测比较有无粘结出水分层现象。以总分100分为最高分进行评价。霜剂的耐寒性得分=100-30(分层严重);得分=100-20(中等分层);得分=100-10(轻微分层)。(分层距离,≤0.2ml的分层属于轻微分层,0.2~0.5ml分层为中等分层,≥0.5ml分层属于严重分层)。
(4)耐热性:将试样倾入两只相同试管内,高度不超过80mm,塞上干净的塞子。把一支待验的试管置于预先调节至40℃的恒温培养箱内,经24h后取出,恢复至室温后与另一支试管的试样进行目测比较有无油水分离现象。耐热性得分=100-30(分层严重);得分=100-20(中等分层);得分=100-10(轻微分层)。(分层距离,≤0.2ml的分层属于轻微分层,0.2~0.5ml分层为中等分层,≥0.5ml分层属于严重分层)。
(5)pH值测定:按GB/T13531.1-2008[9]中规定的方法测定(稀释法)霜剂pH值,称取霜剂1份(精确至0.1g),加入经煮沸冷却后的实验室用水9份,加热至80℃,冷却后过滤去除油块,进行测定。pH值的测定结果以两次测量的平均值表示,判断其是否符合标准GB/T29665-2013[10]中pH 4.0-8.5的要求。以总分100分为最高分进行评价,得分=100分(4.5〈pH〈6.5);得分=80分(4≤pH≤4.5或6.5≤pH≤8.5);得分=0分(pH〈4.0或pH〉8.5)
(6)综合得分=外观*70%+离心稳定性*5%+耐寒性5%+耐热性*5%+pH值*15%。总分100分。
3、实验结果
表1不同原料比例下所得霜剂基质的综合得分对比
由表1可以看出,以本发明特定种类的水相、油相组成的霜剂基质,当控制霜剂基质中甘油聚醚-26为6g、三乙醇胺为3g、羊毛脂为2g、卡波姆为0.2~0.4g、十二烷基硫酸钠为1.25~1.75g、白凡士林为10~12g、硬脂酸为10~14g、其余为水(霜剂基质总重量100g)时,所得霜剂基质外观、离心稳定性、耐寒性、耐热性和pH值的综合效果良好。
当进一步控制卡波姆为0.3~0.4g、十二烷基硫酸钠为1.25~1.5g、白凡士林为10~11.49g、硬脂酸为13~14g时,所得霜剂基质外观、离心稳定性、耐寒性、耐热性和pH值的综合效果显著提高,综合评分均在80分以上。
当进一步控制卡波姆为0.3~0.39g、十二烷基硫酸钠为1.25~1.27g、白凡士林为11~11.49g、硬脂酸为13.89~14g时,所得霜剂基质外观、离心稳定性、耐寒性、耐热性和pH值的综合评分均在95分以上。
实验例2:香附精油抗敏霜的载药量筛选实验
1、实验对象
以实验例1中序号30所示原料为霜剂基质处方,按照表2所示不同的载药量,参照实施例2的方法制得不同载药量的香附精油抗敏霜。
载药量=香附挥发油的质量/霜剂基质的质量×100%
2、评价方法
同实验例1。
3、实验结果
表2不同载药量香附精油抗敏霜的综合评分结果
从表2可以看出,当载药量为1%~5%时,所得香附精油抗敏霜外观、离心稳定性、耐寒性、耐热性和pH值的综合评价都较好,其中,当载药量为3%时,综合得分最高。
说明本发明特定原料种类、特定原料比例组成的霜剂基质与3%载药量的香附挥发油制得的香附精油抗敏霜的综合效果最佳。
实验例3:香附挥发油的抗敏效果
1、实验方法
利用对二硝基氯苯(DNCB)诱导的小鼠迟发型超敏反应(DTH)实验来研究香附挥发油(实施例2步骤(1)制得)的抗敏效果。具体操作如下:
取昆明种小鼠30只,随机均分为空白对照组(K组)、模型组(M组)、香附挥发油低剂量组(D)、中剂量组(Z)、高剂量组(G)(12、16、20g/ml)、阳性对照组(Y组)。除空白对照组注射丙酮溶液外,其余各组每只小鼠背部皮下注射20μl 5%DNCB丙酮溶液致敏,各组以1ml/kg的剂量小鼠连续给药(涂抹香附挥发油)7日,1次/日(空白对照组、模型组给予等体积2%吐温溶液,阳性对照组给予盐酸多塞平乳膏0.117g/kg)。末次给药1h后,以1%DNCB溶液均匀涂于小鼠右耳,每只20μl,激发过敏反应,左耳为对照(空白对照组涂抹丙酮溶液)。涂耳24h后,脱颈椎处死小鼠,剪下双耳耳廓,以直径8mm打孔器摘取左右耳片称重,以两侧耳重的差值作为迟发型超敏反应值,计算肿胀度;摘取胸腺、脾脏称重,以10g体重小鼠的胸腺和脾重量表示脾指数和胸腺指数,并计算致敏潜伏期和抓挠次数。
3、实验结果
表3香附挥发油对小鼠迟发性过敏反应的影响(X±s,n=10)
表3中,与空白对照组比较,**P<0.01,*P<0.05;与模型组比较,△△P<0.01,△P<0.05。
结果如表3所示。与空白对照组比较,模型组、阳性对照组、香附挥发油低剂量组、中剂量组及高剂量组的二次致敏潜伏期都有所缩短,有显著性差异(P<0.01);与模型组相比,阳性对照组与香附挥发油低剂量组的二次致敏潜伏期均有显著性差异,且相比于模型组,其余各给药组二次致敏潜伏期均有延长;二次致敏潜伏期与初次致敏潜伏期比较,除模型组潜伏期缩短外,其余各组潜伏期均有不同程度的延长;与空白对照组比较,除中剂量组外,其余各组二次抓挠次数均与其有显著性差异;二次抓挠次数与模型组比较,空白对照组与低剂量组均有显著性差异(P<0.01),抓挠次数均小于模型组。
实验结果表明,本发明采用的香附挥发油对小鼠迟发性过敏反应的确具有抗敏效果。
实验例4:香附挥发油、香附精油抗敏霜中香附烯酮的含量测定
1、实验方法
采用HPLC方法测试本发明实施例2制得的香附挥发油、实施例2制得的香附精油抗敏霜中的指标性成分香附烯酮的含量。
(1)色谱条件:色谱柱kromasil C18(250mm×4.6ID);流动相为甲醇B-水A(68:32);流速为1.0ml/min;柱温为30℃;检验波长为242nm;进样量为10μl。
(2)对照品溶液的制备:精密称取香附烯酮1.054mg,置于10ml容量瓶中,加甲醇适量使溶解并稀释至刻度,摇匀,即,浓度为0.1054mg/ml的香附烯酮对照品液。
(3)供试品溶液的制备:
a.香附挥发油供试品溶液的制备:精密称取香附挥发油7mg,置25mL容量瓶中加甲醇定容,即得;
b.香附精油抗敏霜供试品溶液的制备:精密称取香附精油抗敏霜0.2g,置容量瓶中加25ml甲醇溶解,密塞,称重,超声1h,放冷,称重用甲醇补足减失质量,摇匀滤过,取续滤液,即得。
(4)香附烯酮标准曲线测试
精密吸取浓度为0.1054mg/ml的香附烯酮对照品溶液,分别进样2、4、6、8、10、12μl,测定香附烯酮色谱峰峰面积。以对照品进样量(μg)为横坐标,色谱峰峰面积为纵坐标,绘制标准曲线,计算回归方程和r2值。
2、测试结果
香附烯酮标准曲线为:y=28.312x+0.0001;相关系数r2=1;线性范围:0.2003μg~1.2021μg。
利用上述方法测得本发明实施例2制得的香附挥发油中香附烯酮的含量为26.585mg/g,本发明实施例2制得的香附精油抗敏霜中香附烯酮的含量为8.045mg/g。
实验例5:香附精油抗敏霜的稳定性测试
1、实验方法
(1)按照实施例2的方法制得4批香附精油抗敏霜,分别加入0.1%的尼铂金甲酯(起防腐作用),将其在常温常压条件下放置30天。按照实验例1的方法评价香附精油抗敏霜放置前、后的外观、离心稳定性、耐寒性、耐热性和pH值,得放置前、后的综合得分。
(2)按照实施例2的方法制得1批香附精油抗敏霜,分别加入0.1%的尼铂金甲酯(起防腐作用),将其在常温常压条件下放置24小时。采用实验例4的HPLC方法,分别在0h、2h、4h、6h、8h、12h、24h测试香附精油抗敏霜中香附烯酮的含量,评价其稳定性。
2、实验结果
(1)放置前,香附精油抗敏霜的综合得分平均值为96.07,放置30天后,香附精油抗敏霜的综合得分平均值为95.13,无明显变化。
(2)在0h、2h、4h、6h、8h、12h、24h测得香附精油抗敏霜中香附烯酮峰面积的相对标准偏差RSD(n=7)为0.5703%,表明供试品溶液在24h内稳定。
实验结果表明,本发明制得的香附精油抗敏霜长期存储稳定性好。
综上,本发明提供了一种霜剂基质和该霜剂基质制得的香附精油抗敏霜。该霜剂基质光泽度、细腻性、涂展性、成形性好,外观、离心稳定性、耐寒性、耐热性和pH值的综合性能优异。以该霜剂基质与香附精油为原料制得的香附精油抗敏霜不仅具有前述优异的综合性能,还具有良好的抗敏效果,有效成分含量高,质量稳定,具有优异的长期储存稳定性,应用前景广阔。
Claims (10)
1.一种霜剂基质,其特征在于:它是由下述重量百分比的原料制得的:甘油聚醚2.00%~10.00%、三乙醇胺2.00%~4.00%、卡波姆0.10%~0.50%、十二烷基硫酸钠0.50%~2.00%、羊毛脂1.00%~5.00%、凡士林10.00%~30.00%、硬脂酸4.0%0~20.00%,其余为水。
2.根据权利要求1所述的霜剂基质,其特征在于:它是由下述重量百分比的原料制得的:甘油聚醚6.00%、三乙醇胺3.00%、卡波姆0.20%~0.40%、十二烷基硫酸钠1.25%~1.75%、羊毛脂2.00%、凡士林10.00%~12.00%、硬脂酸10.00%~14.00%,其余为水;
优选的,它是由下述重量百分比的原料制得的:甘油聚醚6.00%、三乙醇胺3.00%、卡波姆0.20%~0.39%、十二烷基硫酸钠1.25%~1.50%、羊毛脂2.00%、凡士林11.00%~11.49%、硬脂酸10.00%~14.00%,其余为水。
3.根据权利要求2所述的霜剂基质,其特征在于:它是由下述重量百分比的原料制得的:甘油聚醚6.00%、三乙醇胺3.00%、卡波姆0.30%~0.39%、十二烷基硫酸钠1.25%~1.27%、羊毛脂2.00%、凡士林11.00%~11.49%、硬脂酸13.89%~14.00%,其余为水。
4.根据权利要求1~3任一项所述的霜剂基质,其特征在于:所述甘油聚醚为甘油聚醚-26;
和/或,所述凡士林为白凡士林。
5.根据权利要求1~4任一项所述的霜剂基质,其特征在于:所述霜剂基质中还包括防腐剂,所述防腐剂的重量百分比为0.05%~0.20%,优选为0.10%,所述防腐剂优选为尼铂金甲酯。
6.权利要求1~5任一项所述霜剂基质的制备方法,其特征在于:所述方法包括以下步骤:
(1)将甘油聚醚、三乙醇胺、卡波姆、十二烷基硫酸钠、水混合,加热融化,得水相;
(2)将羊毛脂、凡士林、硬脂酸混合,加热融化,得油相;
(3)将水相和油相混合均匀,凝固后即得;
优选的,步骤(1)中,所述加热温度为75~85℃;和/或,步骤(2)中,所述加热温度为75~85℃;和/或,步骤(3)中,所述混合时的温度为75~85℃。
7.一种香附精油抗敏霜,其特征在于:它是由香附精油和霜剂基质组成的,霜剂基质如权利要求1~5任一项所述,香附精油和霜剂基质的重量之比为(1~5):100。
8.根据权利要求7所述的香附精油抗敏霜,其特征在于:所述香附精油和霜剂基质的重量之比为3:100。
9.根据权利要求7或8所述的香附精油抗敏霜,其特征在于:所述香附精油的制备方法为:取香附,加水加热提取,收集挥发油,即得;所述香附与水的质量体积比优选为1:(2~8)g/ml,更优选为1:5g/ml;所述加热温度为100℃;所述提取时间为3~7小时,优选为5小时。
10.权利要求7~9任一项所述香附精油抗敏霜的制备方法,其特征在于:所述方法包括以下步骤:
(1)将甘油聚醚、三乙醇胺、卡波姆、十二烷基硫酸钠、水混合,加热融化,得水相;
(2)将羊毛脂、凡士林、硬脂酸混合,加热融化,得油相;
(3)将香附精油、水相和油相混合均匀,凝固后即得;
优选的,步骤(1)中,所述加热温度为75~85℃;和/或,步骤(2)中,所述加热温度为75~85℃;和/或,步骤(3)中,所述混合时的温度为75~85℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010989101.1A CN111920763A (zh) | 2020-09-18 | 2020-09-18 | 一种香附精油抗敏霜及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010989101.1A CN111920763A (zh) | 2020-09-18 | 2020-09-18 | 一种香附精油抗敏霜及其制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111920763A true CN111920763A (zh) | 2020-11-13 |
Family
ID=73333952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010989101.1A Pending CN111920763A (zh) | 2020-09-18 | 2020-09-18 | 一种香附精油抗敏霜及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111920763A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090023236A (ko) * | 2007-08-31 | 2009-03-04 | (주)콤비메드 | 생약재 발효산물을 포함하는 아토피성 피부염 치료 및/또는예방용 조성물 |
CN104398412A (zh) * | 2014-10-29 | 2015-03-11 | 贵州省健康茶科技有限公司 | 一种甜茶润肤霜及其制作方法 |
CN105997989A (zh) * | 2016-05-17 | 2016-10-12 | 上海通用药业股份有限公司 | 一种用于治疗手足皲裂和角化型手足癣引起皲裂的尿素维e乳膏 |
CN108704049A (zh) * | 2018-08-20 | 2018-10-26 | 吉林鹤立健保健食品有限公司 | 一种具有抗氧化功能的中药组合物及其保健食品的制备方法 |
-
2020
- 2020-09-18 CN CN202010989101.1A patent/CN111920763A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090023236A (ko) * | 2007-08-31 | 2009-03-04 | (주)콤비메드 | 생약재 발효산물을 포함하는 아토피성 피부염 치료 및/또는예방용 조성물 |
CN104398412A (zh) * | 2014-10-29 | 2015-03-11 | 贵州省健康茶科技有限公司 | 一种甜茶润肤霜及其制作方法 |
CN105997989A (zh) * | 2016-05-17 | 2016-10-12 | 上海通用药业股份有限公司 | 一种用于治疗手足皲裂和角化型手足癣引起皲裂的尿素维e乳膏 |
CN108704049A (zh) * | 2018-08-20 | 2018-10-26 | 吉林鹤立健保健食品有限公司 | 一种具有抗氧化功能的中药组合物及其保健食品的制备方法 |
Non-Patent Citations (3)
Title |
---|
FARIDA RAHIM等: "Cream Formulation of Cyperus rotundus L Rhizome Extract for Joint Pain Treatment", 《JOURNAL OF CHEMICAL AND PHARMACEUTICAL SCIENCE》 * |
JEONG HO JIN等: "Anti-allergic Activity of Sesquiterpenes from the Rhizomes of Cyperus rotundus", 《ARCHIVES OF PHARMACAL RESEARCH》 * |
瞿发林: "菌克软膏处方优化的研究", 《实用药物与临床》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113041190B (zh) | 抗氧化组合物、制备方法及用途 | |
AU638932B2 (en) | Pharmaceutical product having epidermial regenerative activity based on the active ingredient of mimosa tenuiflora and process for its obtention | |
CN109745361A (zh) | 一种缓解老年皮肤瘙痒且具有润肤作用的复方皮肤用乳膏剂及其制备方法和应用 | |
CN104800269B (zh) | 一种治疗银屑病的中药外用乳膏及其制备方法 | |
CN105362160A (zh) | 一种含中草药提取物的泥面膜及其制备方法 | |
CN104352884A (zh) | 一种用于治疗稳定期慢性阻塞性肺病的中药组合物 | |
CN110151668A (zh) | 一种高生物效价虾青素化妆品 | |
CN105030562B (zh) | 一种抗过敏复合多糖组合物及其制备方法和应用 | |
CN111920763A (zh) | 一种香附精油抗敏霜及其制备工艺 | |
CN105288418B (zh) | 一种治疗小儿腹泻的微乳凝胶膏剂及其制备方法 | |
CN108686016A (zh) | 一种用于治疗银屑病的中药外用制剂及其制备方法 | |
CN111358719B (zh) | 一种具有防唇炎功能的中草药口红及其制备方法 | |
JP2644531B2 (ja) | 化粧料 | |
CN105267283B (zh) | 一种降血脂的药物组合物及其制备方法 | |
CN104983725B (zh) | 一种具有抗痛经功效的药物组合物及其制备方法 | |
CN107320442B (zh) | 中药外用凝胶及其制备方法 | |
CN113274319A (zh) | 一种晒后舒缓修护及提亮的护肤组合物及制备方法、应用 | |
JP4223574B2 (ja) | 美白用化粧料組成物 | |
CN107320454B (zh) | 都梁滴丸的制备工艺 | |
Nagrare et al. | Physico-Chemical Analysis of Pure and Impure Bhallataka | |
CN112704663B (zh) | 一种枇杷叶熊果酸乳膏的制备方法 | |
CN109394616A (zh) | 一种具有平衡雌激素作用的精油组合物及其应用 | |
CN107582584A (zh) | 一种三七油滴丸及其制备方法 | |
CN110179871A (zh) | 一种治疗湿疹的外用中药组合物及其制备方法 | |
CN114983879B (zh) | 一种厚朴酚漱口水及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201113 |
|
RJ01 | Rejection of invention patent application after publication |